Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients
Recently, the liquid biopsy (LB), a non-invasive and easy to repeat approach, has started to compete with the tissue biopsy (TB) for detection of targets for administration of therapeutic strategies for patients with advanced stages of lung cancer at tumor progression. A LB at diagnosis of late stag...
Main Author: | Paul Hofman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/9/2049 |
Similar Items
-
Next-generation sequencing in liquid biopsy: cancer screening and early detection
by: Ming Chen, et al.
Published: (2019-08-01) -
Real-World Data on Liquid Biopsy Use in Non-Small Cell Lung Cancer in the Community Setting
by: Kathrin Dvir, et al.
Published: (2021-02-01) -
Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC
by: Hestia Mellert, et al.
Published: (2021-01-01) -
The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
by: Yi-Chen Zhang, et al.
Published: (2017-10-01) -
The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer
by: Chenglong Zhao, et al.
Published: (2023-03-01)